FIELD: chemistry; pharmaceutics.
SUBSTANCE: invention relates to a compound according to of formula 1 or a pharmaceutically acceptable salt thereof, which can be used to treat cancer associated with mutations in the KRAS oncogene. In formula 1, X is C1-C5 alkyl; Y is a carboxyl group bonded to C1-C5 alkyl; Z is a carbonyl group bonded to 5-carbamoyl-2,3-dihydro-1H-pyrrole; and W is H. Invention also relates to a pharmaceutical composition, a finished product and a kit for treating cancer associated with mutations in the KRAS oncogene.
EFFECT: there are disclosed new small molecules for targeted splitting of non-susceptible KRAS in cancer therapy.
8 cl, 20 dwg, 8 tbl, 17 ex
formula 1
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
| METHOD OF TREATING CANCER ASSOCIATED WITH A RAS MUTATION | 2016 |
|
RU2736045C2 |
| COMPOSITIONS BASED ON SHP2 INHIBITOR AND METHODS OF CANCER TREATMENT | 2018 |
|
RU2805355C2 |
| DETERMINATION OF CELL SENSITIVITY TO TREATMENT WITH B-Raf INHIBITOR BY DETECTION OF K-ras MUTATION AND LEVELS OF RTK EXPRESSION | 2010 |
|
RU2553379C2 |
| PEPTIDE VACCINE COMPRISING RAS PEPTIDE CONTAINING MUTATIONS, AND CHEMOTHERAPEUTIC AGENT | 2015 |
|
RU2700929C2 |
| COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN TREATMENT OF NRAS MUTATED CANCER | 2015 |
|
RU2683276C2 |
| PHARMACEUTICAL COMPOUND | 2018 |
|
RU2786994C2 |
| COMBINATION THERAPY | 2013 |
|
RU2677245C2 |
| TREATING PATIENTS DIAGNOSED WITH PANCREATIC DUCT ADENOCARCINOMA WITH USING EPIDERMAL GROWTH FACTOR (EGFR) RECEPTOR MONOCLONAL ANTIBODIES | 2016 |
|
RU2728571C2 |
